Multiple drug delivery from a balloon and a prosthesis
Disclosed is an interventional device for delivery of therapeutic agents from an angioplasty balloon and from a prosthesis such as an intraluminal stent. The invention also relates to the method of loading the beneficial agents onto the balloon and the device, as well as the method of delivery of the agents from separate surfaces. The invention also relates to an interventional device having a prosthesis surface that is loaded with a first beneficial agent, and a balloon surface loaded with a second beneficial agent. The invention also relates to a method of loading multiple beneficial agents onto the prosthesis surfaces and the balloon surfaces, and to a method of manufacturing an interventional device for the delivery of a first beneficial agent and a second beneficial agent from separate surfaces.
1. A system for treating vascular disease comprising:
a balloon having an outer surface for temporary contact with a vessel wall when in an expanded state;
a prosthesis mounted on the balloon; and
a coating disposed on at least a portion of the outer surface of the balloon, the coating including an initial amount of zotarolimus, the coating being capable of maintaining a therapeutically effective amount of zotarolimus on the outer surface of the balloon for delivery to a vessel wall, the coating further being capable of retaining between about 4.9% to about 23% of the initial amount of zotarolimus on the outer surface after delivery of the therapeutically effective amount of zotarolimus to the vessel wall.
2. The system of claim 1 , wherein the zotarolimus is disposed on the outer surface at a concentration of from about 3.7 μg/mm 2 to about 7.0 μg/mm 2 .
3. The system of claim 1 , wherein the coating further comprises binders, polymers, solvents, or combinations thereof.
4. The system of claim 1 , wherein the coating further comprises ethanol, Iopromide and acetone.
5. The system of claim 1 , wherein the prosthesis is a stent.
6. The system of claim 5 , wherein the therapeutically effective amount of zotarolimus is effective to maintain at least about 35.7% of a vessel lumen diameter after delivery of the therapeutically effective amount of zotarolimus.
7. The system of claim 5 , wherein the stent is crimped onto the expandable member.
8. The system of claim 5 , wherein the stent is a self-expanding stent.
9. The system of claim 3 , wherein the binder is selected from the group consisting of complex sugars, starches, collagens, and polymeric materials.
10. The system of claim 1 , wherein the coating includes a second beneficial agent.
11. The system of claim 1 , wherein the therapeutically effective amount of the zotarolimus is effective to reduce neointimal formation after delivery of the zotarolimus to the vessel wall.
12. The system of claim 1 , wherein the therapeutically effective amount of the zotarolimus is delivered within about 60 seconds of contact between the expandable member in an expanded condition and the vessel wall.